ArticleNPJ precision oncology2026
Nanoplate based digital PCR assay for effective quantification of plasma HPV circulating tumor DNA.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers.International journal of molecular sciences · 2026Review
- Immune remodeling during cervical cancer chemoradiotherapy: temporal biomarkers and the timing of checkpoint blockade.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
High risk Human papillomavirus (hrHPV) is a leading cause of cervical cancer. Numerous studies have demonstrated the utility of plasma HPV circulating tumor DNA (ctDNA) for disease monitoring in cervical cancer, nevertheless with diverse accuracies. We investigated whether higher sample and reaction volumes using nanoplate based digital PCR (dPCR) system offered enhanced sensitivity and reproducibility, crucial for detecting low-copies of HPV ctDNA. A multiplex dPCR assay was optimized for detecting hrHPV16, 18, and 31 plasma ctDNA from pre-treatment and follow-up plasma samples of 87 cervical cancer patients using Qiagen QIAcuity One dPCR. The assay demonstrated 98% sensitivity and 100% specificity for detecting HPV ctDNA from pre-treatment plasma cell-free DNA (cfDNA). Persistence of HPV ctDNA during follow up associated with disease relapse, while clearance of HPV ctDNA was observed in patients without recurrence. Higher sample and dPCR reaction volumes increased the sensitivity of the test, while HPV ctDNA monitoring effectively reflected disease burden. Trial registration: Clinical Trials Registry of India (CTRI/2020/01/022862); registered on 20 January 2020.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.